Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.
Sponsor: University of California, Davis
You may qualify if…
- ✓ Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.
You may not qualify if…
- ✕ Ages less than 18 and greater than 65
- ✕ Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.
Where it's recruiting
Sacramento
Source: ClinicalTrials.gov · NCT02232191 · last updated 2025-12-05